Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.
Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer
OMICS international has previously organized 10 conferences with 400 conference proceedings and 157 national symposiums, 22 upcoming conferences are in a row under the conference series of organization along with publications of 210 open access articles in 13 International journals.
Disability is the consequence of undesirable interfaces that take place between a person with impairment environment.Disability is abstracted as being a multidimensional involvement for the individual involved.
OMICS International through its Open access initiatives is committed to make genuine and reliable contributions to the scientific community by publishing research work and conference paper related to such disorders. It is known that ConferenceSeries hosts over 700 edge peer reviewed Open Access Journals which contains over 75000 eminent personalities, reputed scientists as editorial board members. Omics International organizes over more than 1000 Global Events annually with support from 1000 more scientific Societies. Its publishing group journals have over 5 million readers and the fame and success of the same can be attributed to the strong editorial board that ensure a quality and quick review process checker.
Fibromyalgia and Chronic pain are the most common cause of serious disability and have a major but often unrecognized, impact on health and social services. There are 30 million people around the world living with a neurological condition which has a significant impact on their lives. Fibromyalgia is estimated to affect 2–8% of the population, with a female to male incidence ratio that is somewhere between 7:1 and 9:1
The findings from the Pharmacor topic entitled Fibromyalgia reveal that, through 2020, an expanding drug-treated population and, to a lesser extent, the uptake of Forest Laboratories/Cypress Bioscience's Savella (milnacipran), Johnson & Johnson/Grünenthal’s will help to offset sales lost to the generic erosion of Cymbalta and Lyrica.The findings also reveal that the U.S. accounted for nearly 80 per cent of major-market fibromyalgia sales in 2010, and in 2020 the U.S. will account for two-thirds of worldwide sales for the indication. The majority of U.S. sales continue to be driven by the leading fibromyalgia-approved therapies—Cymbalta, Lyrica and Savella. In Europe and Japan, market expansion will be constrained by a dearth of approved therapies, lower diagnosis rates and less widespread recognition of the disorder. Because fibromyalgia is a difficult condition to treat its symptoms vary widely from patient to patient and can include pain, depression, fatigue and sleep dysfunction, significant unmet need remains for effective treatments.
List of Best International Conferences
List of Related Societies
List of Related Companies
The varying methodologies taken to defining disability notwithstanding, demographers agree that the worldwide population of persons with debilities are very large. The demographic study shows, estimation of worldwide and worldwide numbers of individuals with disabilities are perplexing. For example, in 2012, the WHO assessed a worldwide population of 6.5 billion individuals. Of those, nearly 650 million people, or 10%, were estimated to be moderately or severely disabled. There is widespread agreement among experts in the field that disability is more common in developing than in established nations. Disability and poverty is thought to be part of a "vicious cycle" in which these constructs are mutually reinforcing.
This page will be updated regularly.
This page was last updated on April 9, 2020